Clinical Trial Update: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating PF-05212384 in combination with other anti-tumor agents and with cisplatin in expansion arms for triple-negative breast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PF-05212384

Snippet

Sponsor: Pfizer | Conditions: Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2021-10-07